Edition:
United States

Ligand Pharmaceuticals Inc (LGND.OQ)

LGND.OQ on NASDAQ Stock Exchange Global Market

110.19USD
26 May 2017
Change (% chg)

$-3.31 (-2.92%)
Prev Close
$113.50
Open
$113.01
Day's High
$113.01
Day's Low
$109.74
Volume
104,358
Avg. Vol
94,246
52-wk High
$139.79
52-wk Low
$87.75

LGND.OQ

Chart for LGND.OQ

About

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such... (more)

Overall

Beta: 1.18
Market Cap(Mil.): $2,313.55
Shares Outstanding(Mil.): 21.00
Dividend: --
Yield (%): --

Financials

  LGND.OQ Industry Sector
P/E (TTM): -- 137.90 17.41
EPS (TTM): -0.18 -- --
ROI: -0.65 -8.48 -5.42
ROE: -0.86 -11.31 -4.68

BRIEF-Ligand Pharmaceuticals enters into agreements with Interventional Analgesix

* On May 22, 2017, entered into a license agreement and a supply agreement with privately-held interventional analgesix, inc

May 23 2017

BRIEF-Ligand reports Q1 earnings per share $0.22

* Q1 earnings per share view $0.63 -- Thomson Reuters I/B/E/S

May 09 2017

BRIEF-Ligand enters commercial license and supply agreements with Marinus Pharmaceuticals for captisol-enabled Ganaxolone

* Ligand enters commercial license and supply agreements with Marinus Pharmaceuticals for captisol-enabled Ganaxolone

Apr 05 2017

BRIEF-Ligand Pharmaceuticals says retrophin announced update on regulatory pathway for late-stage product candidate sparsentan

* Ligand Pharmaceuticals says on March 1 retrophin announced update on regulatory pathway for late-stage product candidate sparsentan - sec filing

Mar 03 2017

BRIEF-Enrollment completed in Ligand's phase 2 trial of lgd-6972 in type 2 diabetes

* Enrollment completed in Ligand's phase 2 trial of lgd-6972 in type 2 diabetes

Feb 27 2017

BRIEF-Dr. Christel Iffland joins Ligand as vice president

* Dr. Christel Iffland joins Ligand as vice president, Antibody Technologies, expands team focused on OMNIAB drug discovery platform Source text for Eikon: Further company coverage:

Feb 14 2017

BRIEF-Ligand expects revenue related to Captisol material sales to be unchanged

* Ligand Pharmaceuticals - companies must adopt standard issued by FASB in may 2014 after january 1, 2017 and no later than january 1, 2018

Jan 18 2017

More From Around the Web

Earnings vs. Estimates